Viking Therapeutics Inc
VKTX
Market Cap$8.35B
Close$
$0.58
99.3% downside
Current Fair Value
99.3% downsideOvervalued by 99.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.35 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 1.26 |
| Outstanding Shares | 110,268,210 |
| Avg 30 Day Volume | 2,680,737 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About Viking Therapeutics Inc
CEO: Brian Lian